Akero 治疗药物Efruxifermin的药物在扭转肝硬化方面很有希望,使库存增加93%。 Akero Therapeutics' Efruxifermin drug shows promise in reversing cirrhosis, boosting stock by 93%.

Akero治疗药物Efruxifermin显示,在二B阶段试验中,新陈代谢性机能障碍相关肝炎(MASH)患者的肝硬化出现逆转,取得了显著成果。 Akero Therapeutics' drug Efruxifermin showed significant results in reversing cirrhosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase IIb trial. 研究发现,39%的接受该药物治疗的病人扭转了肝硬化,而安慰剂组为15%。 The study found that 39% of patients treated with the drug had reversed cirrhosis compared to 15% in the placebo group. 由于取得了积极成果,Akero的股票价格上涨了93.05%,达到市场前交易的50.54美元。 The positive results led to a 93.05% surge in Akero's stock price to $50.54 in pre-market trading.